Wells Fargo
INTS icon

Wells Fargo’s Intensity Therapeutics INTS Stock Holding History

Wells Fargo’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200
Closed -$1.18K – 7443
2026
Q1 		$1.18K Buy
+200
New +$1.63K ﹤0.01% 6319
2024
Q4 		– Sell
-138
Closed -$13.2K – 7128
2024
Q3 		$13.2K Hold
138
– – ﹤0.01% 5731
2024
Q2 		$16.9K Buy
138
+39
+39% +$4.42K ﹤0.01% 5626
2024
Q1 		$12.9K Hold
99
– – ﹤0.01% 5693
2023
Q4 		$21.3K Hold
99
– – ﹤0.01% 5623
2023
Q3 		$9.85K Buy
+99
New +$13.7K ﹤0.01% 5812

Other funds holding INTS

KCIA
Kingsbury Capital Investment Advisors Wilmette, Illinois $118M AUM
KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Wells Fargo's INTS Position: Q2 2026 in Review

Wells Fargo sold out of Intensity Therapeutics (INTS) in Q2 2026, closing a stake of 200 shares — an estimated $1.18K sold.

Wells Fargo first reported a position in INTS in Q3 2023 and held it in 6 quarters. The position peaked at $21.3K in Q4 2023. 17 funds tracked by Wall St. Rank hold INTS as of Q2 2026.

  • Wells Fargo reported no remaining Intensity Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Wells Fargo sold 200 Intensity Therapeutics shares in Q2 2026, an estimated $1.18K.
  • Wells Fargo first reported a position in Intensity Therapeutics in Q3 2023 and held it in 6 quarters.
  • Wells Fargo's Intensity Therapeutics position peaked at $21.3K in Q4 2023.
  • 17 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.